Efficient and reliable scale-up is one of the major hurdles in modern biotechnology. Engineering parameters such as impeller tip speed, oxygen transfer rate, impeller power number (Np) and the impeller power consumption per volume (P/V) are just a few of the parameters that need to be considered to ensure a successful tech transfer from bench to pilot and production scale. The BioFlo® 720 bioreactor control system was designed to save time and to mitigate risks.
British drug developer Mission Therapeutics plc earns $20m milestone
Latest NewsBritish drug developer Mission Therapeutics plc has bagged a $20m milestone payment from Abbvie within the companies’ neurodegenerative disease collaboration.
Bayer takes over Vividion
Latest NewsThe big pharma company is shelling out US$1.5bn in the acquisition of US screening specialist Vividion Therapeutics.
The Ongoing Pandemic Requires Completed SARS-CoV-2 Testing Solutions
ProductsSpectricity raises €14m in Series B round
Latest NewsBelgian semiconductor specialist Spectricity BV has baged €14m to speed up the development of mobile hyperspectral sensors for medical applications.
Sanofi snaps up mRNA partner for US$3.2bn
Latest NewsSanofi further launches into the messenger RNA space with US$3.2bn buy-out of mRNA pioneer Translate Bio.
BioFlo® 720: Experience Seamless Scalability of Your Bioprocess
ProductsEfficient and reliable scale-up is one of the major hurdles in modern biotechnology. Engineering parameters such as impeller tip speed, oxygen transfer rate, impeller power number (Np) and the impeller power consumption per volume (P/V) are just a few of the parameters that need to be considered to ensure a successful tech transfer from bench to pilot and production scale. The BioFlo® 720 bioreactor control system was designed to save time and to mitigate risks.
Abcam to acquire BioVision for $340m
Latest NewsLife sciences tool provider Abcam plc has entered into a definitive agreement to acquire BioVision, Inc. for $340m.
Vaccine development – strategic approach
Sponsored PublicationsThis white paper explores vaccine development during a pandemic, a response to complex challenges that traditional manufacturing methods won’t solve.
Byondis and Glycotope merge platforms to target carbohydrates
Latest NewsCancer and autoimmunity specialist Byondis BV and carbohydrate-targeting antibody company Glycotope have entered into a platform access agreement.
Artios Pharma Ltd raises US-$153m Series C financing
Latest NewsCancer specialist Artios Pharma has raised $153m in a Series C Financing led by Omega Funds and TCG X to progress its clinical pipeline.